%0 Case Reports
%T Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy.
%A Wang Z
%A Huang C
%A Fan W
%A Sun S
%A Li K
%A Liu X
%A Pu J
%A Zhang G
%A Li X
%J Front Oncol
%V 14
%N 0
%D 2024
%M 38595815
%F 5.738
%R 10.3389/fonc.2024.1347282
%X Given their good antitumor effects, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR-sensitive mutations, including exon 19 deletions and exon 21 L858R mutations. EGFR fusion mutations and EGFR amplification are very rare in non-small cell lung cancer (NSCLC). We describe 2 patients with NSCLC harboring EGFR fusion mutations (EGFR-MACF1 and EGFR-GNAT3) combined with EGFR amplification. Both patients received EGFR-TKI treatment, and 1 of them showed an antitumor response.